These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 18155284)

  • 1. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years.
    Dahl R; Kapp A; Colombo G; de Monchy JG; Rak S; Emminger W; Riis B; Grønager PM; Durham SR
    J Allergy Clin Immunol; 2008 Feb; 121(2):512-518.e2. PubMed ID: 18155284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
    Dahl R; Stender A; Rak S
    Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.
    Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F
    J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy.
    Senna GE; Calderon M; Milani M
    Expert Rev Clin Immunol; 2011 Jan; 7(1):21-7. PubMed ID: 21162646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
    Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
    J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.
    Durham SR; Riis B
    Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.
    Kleine-Tebbe J; Ribel M; Herold DA
    Allergy; 2006 Feb; 61(2):181-4. PubMed ID: 16409193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children.
    Ibañez MD; Kaiser F; Knecht R; Armentia A; Schöpfer H; Tholstrup B; Bufe A
    Pediatr Allergy Immunol; 2007 Sep; 18(6):516-22. PubMed ID: 17680910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective.
    Bachert C; Vestenbaek U; Christensen J; Griffiths UK; Poulsen PB
    Clin Exp Allergy; 2007 May; 37(5):772-9. PubMed ID: 17456225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.
    Cox LS; Casale TB; Nayak AS; Bernstein DI; Creticos PS; Ambroisine L; Melac M; Zeldin RK
    J Allergy Clin Immunol; 2012 Dec; 130(6):1327-34.e1. PubMed ID: 23122534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
    Roberts G; Hurley C; Turcanu V; Lack G
    J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals.
    TePas EC; Hoyte EG; McIntire JJ; Umetsu DT
    Ann Allergy Asthma Immunol; 2004 Jan; 92(1):25-31. PubMed ID: 14756461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.
    Rolinck-Werninghaus C; Wolf H; Liebke C; Baars JC; Lange J; Kopp MV; Hammermann J; Leupold W; Bartels P; Gruebl A; Bauer CP; Schnitker J; Wahn U; Niggemann B
    Allergy; 2004 Dec; 59(12):1285-93. PubMed ID: 15507097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy.
    Didier A; Melac M; Montagut A; Lhéritier-Barrand M; Tabar A; Worm M
    Allergy; 2009 Jan; 64(1):166-71. PubMed ID: 19076546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma.
    Nasser S; Vestenbaek U; Beriot-Mathiot A; Poulsen PB
    Allergy; 2008 Dec; 63(12):1624-9. PubMed ID: 19032235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
    Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
    Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study.
    Ott H; Sieber J; Brehler R; Fölster-Holst R; Kapp A; Klimek L; Pfaar O; Merk H
    Allergy; 2009 Sep; 64(9):1394-401. PubMed ID: 19764942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.
    Didier A; Malling HJ; Worm M; Horak F; Jäger S; Montagut A; André C; de Beaumont O; Melac M
    J Allergy Clin Immunol; 2007 Dec; 120(6):1338-45. PubMed ID: 17935764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.